Prescribing Information Visit Patient website
Request a
representative

Comprehensive support designed to help your patients start their prescribed therapy

How to get started with LYNAVOY

  • Send the prescription (LYNAVOY 40 mg twice daily) directly to PANTHERx Rare, our exclusive specialty pharmacy partner
  • Enroll your eligible patient in Interconnect for additional access and support offerings

PANTHERx Rare

PANTHERx Rare provides support for prescription fulfillment, prior authorization processes,* and insurance coordination to help facilitate patient access to prescribed treatment.

Pantherxrare.com
Fax: 1-877-912-0734
Phone: 1-866-347-0951

*Prior authorization support is limited to administrative activities (e.g., benefits investigation, documentation coordination, and status tracking). Clinical determinations, submissions, and appeals remain the responsibility of the prescribing healthcare provider.

Interconnect® Support Services

Interconnect provides additional patient support services, including financial assistance programs, co-pay support, and ongoing personalized support, including check-ins and refill reminders, based on individual patient preferences.

Interconnectsupport.com
Fax: 1-833-636-1742
Phone: 1-844-622-4278

LYNAVOY Support Team

The LYNAVOY Support Team is also available to provide reimbursement guidance throughout the patient journey.

Learn more about the $0†
co-pay option

Our goal is to support patient access to LYNAVOY and provide resources throughout the treatment journey. Access patient support resources through PANTHERx Rare and Interconnect.

Your patients. Our commitment.

Your patients can expect comprehensive, personalized support throughout their prescription journey.

An Interconnect Care Manager will contact your office after your patient is enrolled in Interconnect.

co-pay savings card icon

Co-pay savings card

Patients with commercial insurance may be eligible for the Interconnect Savings Program for LYNAVOY and may be able to pay as little as $0† per month

support icon

Personalized support

Ongoing personalized support and check-ins, tailored to individual patient preferences

education icon

Education

Informational resources for your patients, including refill reminders and answers to questions about their prescription

†Offer not valid for patients enrolled in Medicare, DoD, VA, Medicaid, or other federal or state healthcare programs. For program terms, conditions, and eligibility criteria, visit www.interconnectsupport.com.

Downloadable resources

PDF resources for you and your patients

Download the “How to Start LYNAVOY” brochure, which will provide you with important information for prescribing LYNAVOY.

Open How to Start LYNAVOY PDF

Download the “Doctor/Patient Dialogue Tool,” which will help you have a better discussion with your PBC patients about their itch, and the impact it may have on their lives.

Open Doctor/Patient Dialogue Tool

Important Safety Information

Warnings and Precautions

Liver Test Elevations were observed more commonly in LYNAVOY-treated patients compared to placebo-treated patients.

  • Obtain baseline liver tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], total bilirubin [TB], direct bilirubin [DB], alkaline phosphatase [ALP]) prior to initiating treatment with LYNAVOY and monitor the levels per standard clinical practice for PBC patients during treatment with LYNAVOY.
  • If new liver test elevations occur, monitor ALT, AST, TB, DB, and ALP more frequently.
  • If liver test elevations persist, discontinue LYNAVOY.

Diarrhea was reported as the most common adverse reaction in patients treated with LYNAVOY.

  • If diarrhea occurs, advise patients to monitor for dehydration.
  • Consider interrupting or discontinuing LYNAVOY treatment if diarrhea persists.

Fat-Soluble Vitamin (FSV) Deficiency: LYNAVOY may adversely affect absorption of FSV (i.e., vitamins A, D, E, and K).

  • Obtain serum levels for vitamins A, D, and E and INR prior to initiation of LYNAVOY.
  • Monitor the levels periodically during treatment, along with any clinical manifestations of FSV deficiency.
  • Supplement with FSV if a deficiency is diagnosed.
  • Consider discontinuing LYNAVOY if FSV deficiency persists or worsens despite adequate supplementation.
  • Bleeding was observed more frequently in LYNAVOY-treated patients compared to placebo-treated patients.
    • If bleeding occurs, interrupt LYNAVOY treatment and evaluate for potential FSV deficiency.
    • LYNAVOY can be restarted if FSV deficiency is corrected, levels are maintained, and bleeding has resolved.
  • Bone Fracture has been associated with IBAT inhibitors.
    • Monitor bone health and ensure adequate FSV levels.

Adverse Reactions

The most common adverse reactions (≥5%) are diarrhea, abdominal pain, nausea, increased ALT, hemorrhage, increased AST, headache, dyspepsia, gastroesophageal reflux disease, abdominal distension, dizziness, and arthralgia.

Drug Interactions

  • Effect of Bile Acid Binding Resins on LYNAVOY: Administer at least 4 hours before or 4 hours after administration of LYNAVOY.

To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals 1-844-782-4278 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Please see the full Prescribing Information for LYNAVOY.

Indication:

LYNAVOY (linerixibat) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients.

Limitations of Use: Avoid use of LYNAVOY in patients with decompensated cirrhosis or those with prior or active hepatic decompensation events (e.g. variceal hemorrhage, ascites, hepatic encephalopathy).

References

  1. 1. LYNAVOY (linerixibat) Prescribing Information. Morristown, NJ: Intercept Pharmaceuticals. 2026.
  2. 2. Alfasigma. Linerixibat approved for use in the U.S. for the treatment of cholestatic pruritus in primary biliary cholangitis (PBC). Press release. March 19, 2026. Accessed June 3, 2026. https://www.alfasigma.com/corporate/linerixibat-approved-for-use-in-the-u-s-for-the-treatment-of-cholestatic-pruritus-in-primary-biliary-cholangitis-pbc/
  3. 3. Hegade VS, Kendrick SFW, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389(10074):1114-1123. doi:1016/S0140-6736(17)30319-7
  4. 4. Kode V, Yimam KK. Cholestatic pruritus: pathophysiology, current management approach, and emerging therapies. Curr Hepatol Rep. 2024;23(19):1-14. doi:10.1007/s11901-024-00638-7
  5. 5. Naumann S, Haller D, Eisner P, Schweiggert-Weisz U. Mechanisms of interactions between bile acids and plant compounds—a review. Int J Mol Sci. 2020;21(18):6495. doi:10.3390/ijms21186495
  6. 6. Hirschfield GM, Bowlus CL, Jones DEJ, et al. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11(1):22-33. doi:10.1016/S2468-1253(25)00192-X
  7. 7. Data on File. Intercept Pharmaceuticals, Inc.